INTRODUCTION
The Japanese Pharmaceutical Affairs Law distinguishes cosmetics from quasi-drugs, but specifies that both should have a mild effect on the human body. The amended Pharmaceutical Affairs Law in 2001 repealed the previous approval system, so that manufacturers obtained greater flexibility, while retaining potential liability.
Cosmetics must be safe to use over the long term, so safety assurance is critical. For this purpose, appropriate testing for hazard identification and appropriate exposure assessment are important for risk assessment and calculation of safe exposure levels. It is also important to confirm the safety of cosmetics ingredients, as well as the product itself. Furthermore, post-marketing survey of customers complaints and case reports of adverse effects is necessary to monitor and confirm safety. The procedure of safety assurance is outlined in the first half of this report.
In the second half of this report, I discuss the implications of globalization for cosmetic safety assurance. In particular, development of alternatives to animal testing is an urgent global issue, because the EU cosmetics directive 7th amendment in March, 2013, banned cosmetics company from selling products that have been tested on animals in response to public concern. This situation is expected to accelerate the development of alternatives to animal testing. Here we review the current situation and the prospects for development of alternatives to animal testing, especially skin sensitization testing, which is important for regulatory acceptance.
2 OUTLINE OF CURRENT COSMETIC SAFETY ASSURANCE REQUIREMENTS 2.1 Cosmetic categorization based on Japanese cosmetic regulation The Japanese Pharmaceutical Affairs Law requires that a cosmetic should have only mild effects on the human body 1 . A cosmetic may be rubbed, spread, or applied for cleansing, beautifying, or enhancing the attractiveness of the human body, to change physical appearance, or to maintain skin or hair in a healthy condition. On the other hand, a quasi-drug or medicated cosmetic, such as hair restorer or skin-whitening agent, is categorized as having an intermediate position between a cosmetic and a drug. The activity of both cosmetics and quasi-drugs should be mild, considering that a customer may use them for much of his or her lifetime. Table 1 summarizes the legal distinction between a cosmetic and a quasi-drug. Comprehensive manufacturing and sales approval are required for both items. For a quasidrug, manufacturing, sales, and formulation of ingredients in each item are subject to the requirements of the Japanese Ministry of Health, Labour and Welfare. For a cosmetic, however, manufacturing, sales, and formulating ingredients can be done at a company s own responsibility since the relaxation of cosmetics regulation in 2001. However, labeling of all ingredients is still required. Thus, manufacturers have more flexibility, but remain liable for adverse effects.
Process of cosmetic safety assurance
According to the textbook Toxicology, All substances are poisons: There is none which is not a poison. The right dose differentiates a poison and a remedy.
2 . This means that in formulating cosmetics, we have to take account of concentrations and interactions of components to ensure that effects on the human body are mild and that the cosmetic is safe to use over the long term.
There are various categories of cosmetics and their components amounts and in different locations. In order to assess potential exposure to cosmetics constituents, a person responsible for assessing the safety has to take account of product type, application and usage conditions, concentrations of constituents in the product, amount of product used, frequency, total contact area of skin, contact site skin, mucosa, or nails , reasonably foreseeable misuse, subpopulation adult, child, or sensitive skin , and external conditions sun exposure or not, etc. . Hazard identification is also needed for risk assessment Fig. 1 . Some international toxicological databases are available for hazard assessment. For example, CIR Cosmetic Ingredient Review 3 reviews and SCCS Scientific Committee on Consumer Safety 4 opinions are considered reliable. To assess hazard and potential exposure, test data may also be needed. Appropriate hazard identification and exposure assessment should enable appropriate risk assessment, and allow calculation of a safe dose. A cosmetic product may contain many ingredients. In safety evaluation of each ingredient, the category and potency of the toxicity should be considered, and then the maximum permissible concentration is calculated. In the manufacturing process, formulation is configured using ingredients at safe concentrations based on data or previous usage, then the product safety must be confirmed according to the product type, application usage and potential interaction of ingredients. Table 3 shows endpoints for safety evaluation of cosmetics and quasi-drugs. For cosmetics, 9 endpoints no. 1 to 9 are needed in gereral. In contrast, 12 endpoints no. 1 to 12 are needed for quasi-drugs 1 . Additional endpoints may be needed in particular circumstances. Despite careful safety prediction based on a variety of safety data of ingredients and products, regulations in Japan require the manufacturer to survey customers complaints and case reports of adverse effects post marketing. Such market validation can substantiate the methodology of safety evaluation and its results can thus lead to method improvement Fig. 2 . 
FUTURE ISSUE

Issues accompanying globalization
The shipment value of cosmetics in Japan reached 1400 billion yen in the middle of the 1990 s, and has not changed greatly since then. In other words, the cosmetics market is mature in Japan. Consequently, Japanese cosmetic manufacturers need to expand their overseas markets to achieve growth. Such globalization is associated with various risks and issues.
In particular, local regulation determines the acceptability of cosmetic ingredients in each country, so that some ingredients can be formulated in one country, but not in others. Since regulations may be amended, it is important to have current legal information to ensure compliance.
Fig. 1 Procedure of Safety Assurance.
Moreover, safety testing requirements and endpoints are different in different countries.
Fortunately, International Cooperation on Cosmetics Regulation ICCR 5 is as available as a forum for discussion, communication and international cooperation relating to cosmetic safety. Regulatory authorities and industrial associations from the US, Canada, the EU, and Japan have membership of ICCR. Alternatives to animal testing have been a discussion item since the first conference in 2006.
Progress in alternatives to animal testing
To promote animal welfare, new regulations were implemented last March in the EU. Table 5 shows uptake of alternative test methods in the Organization for Economic Co-operation and Development OECD testing guideline. For primary skin irritation, phototoxicity, eye irritation and mutagenicity, the OECD has adopted alternative methods 10 . However, alternatives to animal testing for skin sensitization and systemic toxicity repeated dose toxicity, reproductive toxicity, ADME and so on have not been established. The EU is sponsoring extensive research to develop alternative methods for systemic toxicological endpoints. Furthermore, some alternatives to skin sensitization testing are being developed based on the OECD guideline. h-CLAT human Cell Line Activation Test , which has been developed by Shiseido Co. Ltd. and Kao Corporation in collaboration, is in the final stage of development and is expected to be listed in the OECD guideline within a few years. An outline of this method is described below. Figure 3a shows a schematic illustration of the mechanism of skin sensitization. Once a chemical sensitizer invades the epidermis, dendritic cells are activated and migrate to regional lymph nodes, where they present the antigen and induce proliferation of antigen-specific T-cells. The LLNA in mice utilizes T-cell proliferation, but h-CLAT utilizes activation of dendritic cells, which occurs in the induction phase of skin sensitization. For example, if cells are exposed to TNCB trinitrochlorobenzene , which is a strong sensitizer, the cell-surface characteristics change data not shown , and this change can be quantified Fig.  3b by measuring cell-surface antigens. Therefore, sensitization potential can be evaluated by using cultivated cells. Ashikaga reported that there was a good relationship between h-CLAT and LLNA for 100 chemicals 11 .
Development of alternatives to animal testing is likely to accelerate further in the future.
CONCLUDING REMARKS
The key points of this review are itemized below. The Japanese Pharmaceutical Affair Law defines and distinguishes cosmetics and quasi-drugs, which are required to have mild effects on the human body. Cosmetic safety requires safety assessment of both ingredients and products. Post marketing surveillance is a key aspect of safety assessment, utilizing customers complaints and case reports of adverse effects. Accompanying globalization, compliance with different regulations in various markets is a major issue for producers. The animal testing ban in Europe is likely to extend globally in due course, and further development of alternatives to animal testing remains an urgent global issue.
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